Events & Resources

Learning Center
Read through guides, explore resource hubs, and sample our coverage.
Learn More
Events
Register for an upcoming webinar and track which industry events our analysts attend.
Learn More
Podcasts
Listen to our podcast, Behind the Numbers for the latest news and insights.
Learn More

About

Our Story
Learn more about our mission and how EMARKETER came to be.
Learn More
Our Clients
Key decision-makers share why they find EMARKETER so critical.
Learn More
Our People
Take a look into our corporate culture and view our open roles.
Join the Team
Our Methodology
Rigorous proprietary data vetting strips biases and produces superior insights.
Learn More
Newsroom
See our latest press releases, news articles or download our press kit.
Learn More
Contact Us
Speak to a member of our team to learn more about EMARKETER.
Contact Us

WeightWatchers will start offering compounded GLP-1 weight-loss drugs

The news: Pushed by consumer demand and a shortage of the brand-name GLP-1 medications, WeightWatchers (WW) has joined a growing list of companies that will be offering compounded semaglutide (marketed by Novo Nordisk as Ozempic and Wegovy) to its members.

  • Last year, WW entered the weight loss drug market when it acquired Sequence, a telehealth company that prescribes the meds.
  • Starting at $189 per month, the new offering is an add-on to WW’s existing weight management program, which includes access to clinicians, dieticians, and treatments.
  • Shares of WW soared ~50% following the announcement, but are still down nearly 80% for the year.

You've read 0 of 2 free articles this month.

Create an account for uninterrupted access to select articles.
Create a Free Account